Disparities in metabolic dysfunction-associated steatotic liver disease and cardiometabolic conditions in low and lower middle-income countries: a systematic analysis from the global burden of disease study 2019

IF 10.8 1区 医学 Q1 ENDOCRINOLOGY & METABOLISM Metabolism: clinical and experimental Pub Date : 2024-06-26 DOI:10.1016/j.metabol.2024.155958
Pojsakorn Danpanichkul , Kanokphong Suparan , Priyata Dutta , Chuthathip Kaeosri , Banthoon Sukphutanan , Yanfang Pang , Narathorn Kulthamrongsri , Methasit Jaisa-aad , Cheng Han Ng , Margaret Teng , Masahito Nakano , Asahiro Morishita , Naim Alkhouri , Ju Dong Yang , Vincent L. Chen , Donghee Kim , Michael B. Fallon , Luis Antonio Diaz , Juan Pablo Arab , Christos S. Mantzoros , Karn Wijarnpreecha
{"title":"Disparities in metabolic dysfunction-associated steatotic liver disease and cardiometabolic conditions in low and lower middle-income countries: a systematic analysis from the global burden of disease study 2019","authors":"Pojsakorn Danpanichkul ,&nbsp;Kanokphong Suparan ,&nbsp;Priyata Dutta ,&nbsp;Chuthathip Kaeosri ,&nbsp;Banthoon Sukphutanan ,&nbsp;Yanfang Pang ,&nbsp;Narathorn Kulthamrongsri ,&nbsp;Methasit Jaisa-aad ,&nbsp;Cheng Han Ng ,&nbsp;Margaret Teng ,&nbsp;Masahito Nakano ,&nbsp;Asahiro Morishita ,&nbsp;Naim Alkhouri ,&nbsp;Ju Dong Yang ,&nbsp;Vincent L. Chen ,&nbsp;Donghee Kim ,&nbsp;Michael B. Fallon ,&nbsp;Luis Antonio Diaz ,&nbsp;Juan Pablo Arab ,&nbsp;Christos S. Mantzoros ,&nbsp;Karn Wijarnpreecha","doi":"10.1016/j.metabol.2024.155958","DOIUrl":null,"url":null,"abstract":"<div><h3>Objective</h3><p>Metabolic dysfunction-associated steatotic liver disease (MASLD) and cardiometabolic conditions affect populations across economic strata. Nevertheless, there are limited epidemiological studies addressing these diseases in low (LICs) and lower-middle-income countries (lower MICs). Therefore, an analysis of the trend of MASLD and cardiometabolic conditions in these countries is necessary.</p></div><div><h3>Methods</h3><p>From 2000 to 2019, jointpoint regression analysis was employed to calculate the prevalence, mortality, and disability-adjusted life years (DALYs) for cardiometabolic conditions including MASLD, type 2 diabetes mellitus (T2DM), dyslipidemia (DLP), hypertension (HTN), obesity, peripheral artery disease (PAD), atrial fibrillation and flutter (AF/AFL), ischemic heart disease (IHD), stroke, and chronic kidney disease from HTN and T2DM, in LICs and lower MICs (according to the World Bank Classification 2019) using the Global Burden of Disease 2019 data.</p></div><div><h3>Results</h3><p>Among the eleven cardiometabolic conditions, MASLD (533.65 million), T2DM (162.96 million), and IHD (76.81 million) had the highest prevalence in LICs and Lower MICs in 2019. MASLD represented the largest proportion of global prevalence in these countries (43 %). From 2000 to 2019, mortality in LICs and lower MICs increased in all cardiometabolic conditions, with obesity-related mortality having the highest increase (+134 %). During this timeframe, there were increased age-standardized death rates (ASDR) from obesity, PAD, and AF/AFL. From all conditions, the DALYs-to-prevalence ratio was higher in LICs and lower MICs than the global average.</p></div><div><h3>Conclusion</h3><p>The burden of MASLD and cardiometabolic conditions is increasing worldwide, with LICs and lower MICs experiencing higher (DALYs) disability per prevalence. As these conditions are preventable, counteracting these trends requires not only the modification of ongoing actions but also the strategizing of immediate interventions.</p></div>","PeriodicalId":18694,"journal":{"name":"Metabolism: clinical and experimental","volume":"158 ","pages":"Article 155958"},"PeriodicalIF":10.8000,"publicationDate":"2024-06-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Metabolism: clinical and experimental","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0026049524001859","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0

Abstract

Objective

Metabolic dysfunction-associated steatotic liver disease (MASLD) and cardiometabolic conditions affect populations across economic strata. Nevertheless, there are limited epidemiological studies addressing these diseases in low (LICs) and lower-middle-income countries (lower MICs). Therefore, an analysis of the trend of MASLD and cardiometabolic conditions in these countries is necessary.

Methods

From 2000 to 2019, jointpoint regression analysis was employed to calculate the prevalence, mortality, and disability-adjusted life years (DALYs) for cardiometabolic conditions including MASLD, type 2 diabetes mellitus (T2DM), dyslipidemia (DLP), hypertension (HTN), obesity, peripheral artery disease (PAD), atrial fibrillation and flutter (AF/AFL), ischemic heart disease (IHD), stroke, and chronic kidney disease from HTN and T2DM, in LICs and lower MICs (according to the World Bank Classification 2019) using the Global Burden of Disease 2019 data.

Results

Among the eleven cardiometabolic conditions, MASLD (533.65 million), T2DM (162.96 million), and IHD (76.81 million) had the highest prevalence in LICs and Lower MICs in 2019. MASLD represented the largest proportion of global prevalence in these countries (43 %). From 2000 to 2019, mortality in LICs and lower MICs increased in all cardiometabolic conditions, with obesity-related mortality having the highest increase (+134 %). During this timeframe, there were increased age-standardized death rates (ASDR) from obesity, PAD, and AF/AFL. From all conditions, the DALYs-to-prevalence ratio was higher in LICs and lower MICs than the global average.

Conclusion

The burden of MASLD and cardiometabolic conditions is increasing worldwide, with LICs and lower MICs experiencing higher (DALYs) disability per prevalence. As these conditions are preventable, counteracting these trends requires not only the modification of ongoing actions but also the strategizing of immediate interventions.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
中低收入国家代谢功能障碍相关脂肪肝和心脏代谢疾病的差异:2019 年全球疾病负担研究的系统分析。
目的:代谢功能障碍相关性脂肪肝(MASLD)和心脏代谢疾病影响着各个经济阶层的人群。然而,针对低收入国家(LICs)和中低收入国家(MICs)这些疾病的流行病学研究十分有限。因此,有必要对这些国家的 MASLD 和心脏代谢疾病的趋势进行分析:方法:从 2000 年到 2019 年,采用联合点回归分析法计算了包括 MASLD、2 型糖尿病 (T2DM)、血脂异常 (DLP)、高血压 (HTN)、肥胖症在内的心脏代谢疾病的患病率、死亡率和残疾调整生命年 (DALYs)、利用《2019 年全球疾病负担》数据,对低收入国家和中等收入国家(根据世界银行 2019 年分类)的外周动脉疾病(PAD)、心房颤动和扑动(AF/AFL)、缺血性心脏病(IHD)、中风以及高血压和 T2DM 引起的慢性肾病进行了分析。结果2019 年,在 11 种心脏代谢疾病中,MASLD(5.3365 亿)、T2DM(1.6296 亿)和 IHD(7681 万)在低收入国家和低中等收入国家的发病率最高。在这些国家,MASLD 在全球患病率中所占比例最大(43%)。从 2000 年到 2019 年,在所有心脏代谢疾病中,低收入国家和低中等收入国家的死亡率都有所上升,其中与肥胖相关的死亡率上升幅度最大(+134%)。在这一时期,肥胖、急性心肌梗死和房颤/急性心力衰竭的年龄标准化死亡率(ASDR)均有所上升。在所有疾病中,低收入国家和中等收入国家的残疾调整寿命年数与发病率之比高于全球平均水平:结论:在全球范围内,MASLD 和心脏代谢疾病的负担日益加重,低收入国家和低中等收入国家的残疾率与发病率之比更高。由于这些疾病是可以预防的,因此要扭转这些趋势,不仅需要改变正在采取的行动,还需要制定即时干预措施的战略。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Metabolism: clinical and experimental
Metabolism: clinical and experimental 医学-内分泌学与代谢
CiteScore
18.90
自引率
3.10%
发文量
310
审稿时长
16 days
期刊介绍: Metabolism upholds research excellence by disseminating high-quality original research, reviews, editorials, and commentaries covering all facets of human metabolism. Consideration for publication in Metabolism extends to studies in humans, animal, and cellular models, with a particular emphasis on work demonstrating strong translational potential. The journal addresses a range of topics, including: - Energy Expenditure and Obesity - Metabolic Syndrome, Prediabetes, and Diabetes - Nutrition, Exercise, and the Environment - Genetics and Genomics, Proteomics, and Metabolomics - Carbohydrate, Lipid, and Protein Metabolism - Endocrinology and Hypertension - Mineral and Bone Metabolism - Cardiovascular Diseases and Malignancies - Inflammation in metabolism and immunometabolism
期刊最新文献
Reducing the global prevalence of cardiometabolic risk factors: a bet worth winning Bilirubin bioconversion to urobilin in the gut-liver-kidney axis: A biomarker for insulin resistance in the Cardiovascular-Kidney-Metabolic (CKM) Syndrome. An updated overview on hepatocellular carcinoma in patients with Metabolic dysfunction-Associated Steatotic Liver Disease: Trends, pathophysiology and risk-based surveillance Accurate non-invasive detection of MASH with fibrosis F2-F3 using a lightweight machine learning model with minimal clinical and metabolomic variables. Metabolic dysfunction-associated steatotic liver disease and urinary system cancers: Mere coincidence or reason for concern?
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1